Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Large Cap

Large Cap

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients

By Vandana Singh
December 9, 7:14 AM
AstraZeneca Plc (NASDAQ:AZN) reported initial data from the TROPION-PanTumor01 Phase 1 trial of datopotamab deruxtecan (Dato-DXd). The data showed encouraging and…

AZN

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials

By Vandana Singh
December 8, 2:41 PM
AstraZeneca Plc (NASDAQ:AZN) announced detailed results from the SERENA-2 Phase 2 trial of camizestrant in pretreated post-menopausal patients with estrogen receptor…

AZN

Read More
2 minute read
  • Commodities
  • General
  • Large Cap
  • Markets
  • News
  • Real Estate
  • REIT
  • Top Stories

Blackstone’s COO Is Bullish On BREIT And This Could Be The Reason

By AJ Fabino
December 8, 2:24 PM
Blackstone Inc (NYSE: BX) has taken heat over the past week for limiting withdrawals from its $69 billion private BREIT, or Blackstone Real E

BX

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

FDA Authorizes Pfizer/BioNTech And Moderna’s Bivalent COVID Shots For 6 Months Old

By Vandana Singh
December 8, 2:18 PM
The FDA has authorized COVID-19 shots from Moderna Inc (NASDAQ:MRNA) and Pfizer Inc (NYSE:PFE)/ BioNTech SE (NASDAQ:BNTX) targeting the original coronavirus and Omicron sub-variants…

BNTX

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Small Cap
  • Trading Ideas

Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder

By Vandana Singh
December 8, 11:58 AM
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Entrada Therapeutics Inc (NASDAQ:TRDA) announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV)…

TRDA

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Novartis’ Rare Blood Disorder Therapy Aces Second Late-Stage Trial

By Vandana Singh
December 8, 11:46 AM
Novartis AG’s (NYSE:NVS) Phase 3 APPOINT-PNH study of iptacopan in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH) met its primary endpoint. …

NVS

Read More
1 minute read
  • Fintech
  • General
  • Hedge Funds
  • Large Cap
  • News
  • Real Estate
  • REIT

Blackstone CEO Says Worried Investors Behind REIT Redemptions

By Vandana Singh
December 8, 11:35 AM
Blackstone Inc's (NYSE: BX) CEO Stephen Schwarzman said that worried investors drove redemptions from its $69 billion unlisted real estate income trust (REIT) due to market volatility rather than dissatisfaction with the fund.

BX

Read More
1 minute read
  • General
  • Government
  • Large Cap
  • News

Airbus CEO Expects Positive Demand For Wide-Body Jets In Next Two Years

By Vandana Singh
December 8, 9:15 AM
In an interview with reporters, Airbus SE (OTC: EADSY) (OTC: EADSF) CEO Guillaume Faury said he expects 2023 and 2024 will be…

EADSF

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • Large Cap
  • News

Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration

By Vandana Singh
December 8, 7:19 AM
Revolution Medicines Inc (NASDAQ:RVMD) announced that Sanofi SA (NASDAQ:SNY) has terminated global SHP2 development and commercialization collaboration.  Following termination, Revolution Medicines will…

AMGN

Read More
2 minute read
  • Biotech
  • Earnings
  • Gaming
  • General
  • Large Cap
  • Markets
  • News
  • Small Cap
  • Top Stories

Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors’ Attention Today

By Bhavik Nair
December 7, 8:45 PM
U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee meeting beginning to weigh on investors’ minds.

AAPL

Posts pagination

Previous 1 … 374 375 376 … 437 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service